{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:19:42Z","timestamp":1793110782792,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Latest clinical research shows that trimetazidine therapy during the perioperative period relieves endothelial dysfunction in patients with unstable angina induced by percutaneous coronary intervention. In this study we investigated the effects of TMZ on myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice. Cardiac hypertrophy was induced in mice by transverse aortic constriction (TAC) surgery. TAC mice were administered trimetazidine (2.8\u2009mg\/100\u2009\u00b5L, i.g.) for 28 consecutive days. We showed that trimetazidine administration significantly increased blood vessel density in the left ventricular myocardium and abrogated cardiac dysfunction in TAC mice. Co-administration of a specific HSF1 inhibitor KRIBB11 (1.25\u2009mg\/100\u2009\u00b5L, i.h.) abrogated the angiogenesis-promoting effects of trimetazidine in TAC mice. Using luciferase reporter and electrophoretic mobility shift assays we demonstrated that the transcription factor HSF1 bound to the promoter region of VEGF-A, and the transcriptional activity of HSF1 was enhanced upon trimetazidine treatment. In molecular docking analysis we found that trimetazidine directly bound to Akt via a hydrogen bond with Asp292 and a pi\u2013pi bond with Trp80. In norepinephrine-treated HUVECs, we showed that trimetazidine significantly increased the phosphorylation of Akt and the synergistic nuclear translocation of Akt and HSF1, as well as the binding of Akt and HSF1 in the nucleus. These results suggest that trimetazidine enhances myocardial angiogenesis through a direct interaction with Akt and promotion of nuclear translocation of HSF1, and that trimetazidine may be used for the treatment of myocardial angiogenic disorders in hypertensive patients.<\/jats:p>","DOI":"10.1038\/s41401-022-00877-8","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T09:02:46Z","timestamp":1645779766000},"page":"2550-2561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter"],"prefix":"10.1038","volume":"43","author":[{"given":"Hong-yang","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-zhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-jian","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959\u201368. https:\/\/doi.org\/10.1001\/jama.2013.184182.","journal-title":"JAMA"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He. J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(05)17741-1.","journal-title":"Lancet"},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","volume":"324","author":"P Muntner","year":"2020","unstructured":"Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324:1190\u2013200. https:\/\/doi.org\/10.1001\/jama.2020.14545.","journal-title":"JAMA"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","volume":"13","author":"B Ziaeian","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368\u201378. https:\/\/doi.org\/10.1038\/nrcardio.2016.25.","journal-title":"Nat Rev Cardiol."},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","volume":"115","author":"S Boudina","year":"2007","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.679597.","journal-title":"Circulation"},{"key":"877_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/164_2016_74","volume":"243","author":"F Orso","year":"2017","unstructured":"Orso F, Fabbri G, Pietro Maggioni A. Epidemiology of heart failure. Handb Exp Pharmacol. 2017;243:15\u201333. https:\/\/doi.org\/10.1007\/164_2016_74.","journal-title":"Handb Exp Pharmacol"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCRESAHA.114.300507","volume":"114","author":"T Oka","year":"2014","unstructured":"Oka T, Akazawa H, Naito AT, Komuro. I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res. 2014;114:565\u201371. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.300507.","journal-title":"Circ Res."},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.112.096479","volume":"126","author":"T Shigeta","year":"2012","unstructured":"Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012;126:1838\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.096479.","journal-title":"Circulation"},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15420\/cfr.2016:13:1","volume":"2","author":"I Milinkovi\u0107","year":"2016","unstructured":"Milinkovi\u0107 I, Rosano G, Lopatin Y, Seferovi\u0107 PM. The role of ivabradine and trimetazidine in the New ESC HF Guidelines. Card Fail Rev. 2016;2:123\u20139. https:\/\/doi.org\/10.15420\/cfr.2016:13:1.","journal-title":"Card Fail Rev"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"1255.","DOI":"10.3389\/fphar.2020.01255","volume":"11","author":"H Li","year":"2020","unstructured":"Li H, Ma Z, Zhai Y, Lv C, Yuan P, Zhu F, et al. Trimetazidine ameliorates myocardial metabolic remodeling in isoproterenol-induced rats through regulating ketone body metabolism via activating AMPK and PPAR \u03b1. Front Pharmacol. 2020;11:1255. https:\/\/doi.org\/10.3389\/fphar.2020.01255.","journal-title":"Front Pharmacol"},{"key":"877_CR11","first-page":"188","volume":"20","author":"Y-S Chu","year":"2016","unstructured":"Chu Y-S, Li D-X, Zhang M, Jiang. T-M. Trimetazidine hydrochloride as a new treatment for patients with peripheral vascular disease\u2212an exploratory trial. Eur Rev Med Pharmacol Sci. 2016;20:188\u201393.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s11255-019-02308-w","volume":"51","author":"X Lian","year":"2019","unstructured":"Lian X, He W, Zhan H, Chen J, Tan N, He P, et al. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization. Int Urol Nephrol. 2019;51:2267\u201372. https:\/\/doi.org\/10.1007\/s11255-019-02308-w.","journal-title":"Int Urol Nephrol"},{"key":"877_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00109-018-1664-3","volume":"96","author":"S Wu","year":"2018","unstructured":"Wu S, Chang G, Gao L, Jiang D, Wang L, Li G, et al. Trimetazidine protects against myocardial ischemia\/reperfusion injury by inhibiting excessive autophagy. J Mol Med. 2018;96:791\u2013806. https:\/\/doi.org\/10.1007\/s00109-018-1664-3.","journal-title":"J Mol Med."},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15420\/cfr.2018.18.2","volume":"4","author":"GM Rosano","year":"2018","unstructured":"Rosano GM, Vitale. C. Metabolic modulation of cardiac metabolism in heart failure. Card Fail Rev. 2018;4:99\u2013103. https:\/\/doi.org\/10.15420\/cfr.2018.18.2.","journal-title":"Card Fail Rev."},{"key":"877_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.res.86.5.580","volume":"86","author":"PF Kantor","year":"2000","unstructured":"Kantor PF, Lucien A, Kozak R, Lopaschuk. GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580\u20138. https:\/\/doi.org\/10.1161\/01.res.86.5.580.","journal-title":"Circ Res"},{"key":"877_CR16","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/01.RES.0000086964.07404.A5","volume":"93","author":"GD Lopaschuk","year":"2003","unstructured":"Lopaschuk GD, Barr R, Thomas PD, Dyck. JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93:e33\u20137. https:\/\/doi.org\/10.1161\/01.RES.0000086964.07404.A5.","journal-title":"Circ Res."},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000369246","volume":"130","author":"Y-C Liu","year":"2015","unstructured":"Liu Y-C, Li L, Su Q, Liu T, Tang. Z. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization. Cardiology. 2015;130:130\u20136. https:\/\/doi.org\/10.1159\/000369246.","journal-title":"Cardiology"},{"key":"877_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.14744\/AnatolJCardiol.2019.83648","volume":"22","author":"W Zheng","year":"2019","unstructured":"Zheng W, Liu C. The cystathionine gamma-lyase\/hydrogen sulfide pathway mediates the trimetazidine-induced protection of H9c2 cells against hypoxia\/reoxygenation-induced apoptosis and oxidative stress. Anatol J Cardiol. 2019;22:102\u201311. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2019.83648.","journal-title":"Anatol J Cardiol"},{"key":"877_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cvr\/cvq181","volume":"88","author":"X Liu","year":"2010","unstructured":"Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. 2010;88:150\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvq181.","journal-title":"Cardiovasc Res"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3892\/etm.2019.7705","volume":"18","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Li S, Quan E, Zhang H, Wu Y, Luo Y, et al. Trimetazidine inhibits cardiac fibrosis by reducing reactive oxygen species and downregulating connective tissue growth factor in streptozotocin-induced diabetic rats. Exp Ther Med. 2019;18:1477\u201385. https:\/\/doi.org\/10.3892\/etm.2019.7705.","journal-title":"Exp Ther Med"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"2015.","DOI":"10.3389\/fimmu.2018.02015","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Wang B, Lai J, Braunstein Z, He M, Ruan G, et al. Trimetazidine attenuates cardiac dysfunction in endotoxemia and sepsis by promoting neutrophil migration. Front Immunol. 2018;9:2015. https:\/\/doi.org\/10.3389\/fimmu.2018.02015.","journal-title":"Front Immunol"},{"key":"877_CR22","doi-asserted-by":"publisher","first-page":"e40424.","DOI":"10.1371\/journal.pone.0040424","volume":"7","author":"X Zhou","year":"2012","unstructured":"Zhou X, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One. 2012;7:e40424. https:\/\/doi.org\/10.1371\/journal.pone.0040424.","journal-title":"PLoS One"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","volume":"396","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396:830\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)31790-6.","journal-title":"Lancet"},{"key":"877_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.7326\/0003-4819-115-4-283","volume":"115","author":"KK Lai","year":"1991","unstructured":"Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2\u2019,3\u2019-dideoxyinosine (ddI). Ann Intern Med. 1991;115:283\u20134. https:\/\/doi.org\/10.7326\/0003-4819-115-4-283.","journal-title":"Ann Intern Med."},{"key":"877_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27:221\u201334. https:\/\/doi.org\/10.1007\/s10822-013-9644-8.","journal-title":"J Comput Aided Mol Des."},{"key":"877_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/ATVBAHA.119.313757","volume":"40","author":"S Lu","year":"2020","unstructured":"Lu S, Strand KA, Mutryn MF, Tucker RM, Jolly AJ, Furgeson SB, et al. PTEN (Phosphatase and Tensin Homolog) protects against Ang II (Angiotensin II)-induced pathological vascular fibrosis and remodeling-brief report. Arterioscler Thromb Vasc Biol. 2020;40:394\u2013403. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313757.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"877_CR27","doi-asserted-by":"publisher","first-page":"24.","DOI":"10.1038\/s41392-019-0055-8","volume":"4","author":"H Zheng","year":"2019","unstructured":"Zheng H, Tie Y, Fang Z, Wu X, Yi T, Huang S, et al. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther. 2019;4:24. https:\/\/doi.org\/10.1038\/s41392-019-0055-8.","journal-title":"Signal Transduct Target Ther."},{"key":"877_CR28","doi-asserted-by":"publisher","first-page":"373.","DOI":"10.1186\/s13287-020-01881-7","volume":"11","author":"J Sun","year":"2020","unstructured":"Sun J, Shen H, Shao L, Teng X, Chen Y, Liu X, et al. HIF-1\u03b1 overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis. Stem Cell Res Ther. 2020;11:373. https:\/\/doi.org\/10.1186\/s13287-020-01881-7.","journal-title":"Stem Cell Res Ther"},{"key":"877_CR29","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1021\/ja412128w","volume":"136","author":"H Chen","year":"2014","unstructured":"Chen H, Long H, Cui X, Zhou J, Xu M, Yuan G. Exploring the formation and recognition of an important G-quadruplex in a HIF1\u03b1 promoter and its transcriptional inhibition by a benzo[c]phenanthridine derivative. J Am Chem Soc. 2014;136:2583\u201391. https:\/\/doi.org\/10.1021\/ja412128w.","journal-title":"J Am Chem Soc"},{"key":"877_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1385\/1-59259-860-9:023","volume":"294","author":"LG Rodriguez","year":"2005","unstructured":"Rodriguez LG, Wu X, Guan J-L. Wound-healing assay. Methods Mol Biol. 2005;294:23\u20139. https:\/\/doi.org\/10.1385\/1-59259-860-9:023.","journal-title":"Methods Mol Biol"},{"key":"877_CR31","doi-asserted-by":"publisher","first-page":"362.","DOI":"10.3389\/fphar.2019.00362","volume":"10","author":"G Behnammanesh","year":"2019","unstructured":"Behnammanesh G, Durante ZE, Peyton KJ, Martinez-Lemus LA, Brown SM, Bender SB, et al. Canagliflozin inhibits human endothelial cell proliferation and tube formation. Front Pharmacol. 2019;10:362. https:\/\/doi.org\/10.3389\/fphar.2019.00362.","journal-title":"Front Pharmacol."},{"key":"877_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.mcb.2018.09.003","volume":"149","author":"SL Wertz","year":"2019","unstructured":"Wertz SL, Desimine VL, Maning J, McCrink KA, Lymperopoulos A. Co-IP assays for measuring GPCR-arrestin interactions. Methods Cell Biol. 2019;149:205\u201313. https:\/\/doi.org\/10.1016\/bs.mcb.2018.09.003.","journal-title":"Methods Cell Biol"},{"key":"877_CR33","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/jcmm.14872","volume":"24","author":"X Tian","year":"2020","unstructured":"Tian X, Zhou N, Yuan J, Lu L, Zhang Q, Wei M, et al. Heat shock transcription factor 1 regulates exercise-induced myocardial angiogenesis after pressure overload via HIF-1\u03b1\/VEGF pathway. J Cell Mol Med. 2020;24:2178\u201388. https:\/\/doi.org\/10.1111\/jcmm.14872.","journal-title":"J Cell Mol Med."},{"key":"877_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.yjmcc.2011.07.030","volume":"51","author":"Y Zou","year":"2011","unstructured":"Zou Y, Li J, Ma H, Jiang H, Yuan J, Gong H, et al. Heat shock transcription factor 1 protects heart after pressure overload through promoting myocardial angiogenesis in male mice. J Mol Cell Cardiol. 2011;51:821\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.07.030.","journal-title":"J Mol Cell Cardiol"},{"key":"877_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ehjcvp\/pvv051","volume":"2","author":"CP McCarthy","year":"2016","unstructured":"McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Hear J Cardiovasc Pharmacother. 2016;2:266\u201372. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv051.","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"877_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","volume":"293","author":"M Marzilli","year":"2019","unstructured":"Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019;293:39\u201344. https:\/\/doi.org\/10.1016\/j.ijcard.2019.05.063.","journal-title":"Int J Cardiol"},{"key":"877_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jphs.2019.01.016","volume":"139","author":"S-G Tang","year":"2019","unstructured":"Tang S-G, Liu X-Y, Wang S-P, Wang H-H, Jovanovic A, Tan W. Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2\/TRPC3-induced oxidative stress. J Pharmacol Sci. 2019;139:311\u20138. https:\/\/doi.org\/10.1016\/j.jphs.2019.01.016.","journal-title":"J Pharmacol Sci"},{"key":"877_CR38","doi-asserted-by":"publisher","first-page":"8459","DOI":"10.12659\/MSM.911317","volume":"24","author":"S Zheng","year":"2018","unstructured":"Zheng S, Du Y, Peng Q, Fan X, Li J, Chen M. Trimetazidine protects against atherosclerosis by changing energy charge and oxidative stress. Med Sci Monit Int Med J Exp Clin Res. 2018;24:8459\u201368. https:\/\/doi.org\/10.12659\/MSM.911317.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"877_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.14744\/AnatolJCardiol.2017.7771","volume":"18","author":"W Shi","year":"2017","unstructured":"Shi W, Shangguan W, Zhang Y, Li C, Li G. Effects of trimetazidine on mitochondrial respiratory function, biosynthesis, and fission\/fusion in rats with acute myocardial ischemia. Anatol J Cardiol. 2017;18:175\u201381. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2017.7771.","journal-title":"Anatol J Cardiol"},{"key":"877_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bcp.2014.07.022","volume":"91","author":"J Kuzmicic","year":"2014","unstructured":"Kuzmicic J, Parra V, Verdejo HE, L\u00f3pez-Crisosto C, Chiong M, Garc\u00eda L, et al. Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes. Biochem Pharmacol. 2014;91:323\u201336. https:\/\/doi.org\/10.1016\/j.bcp.2014.07.022.","journal-title":"Biochem Pharmacol."},{"key":"877_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signaling: navigating the network. Cell. 2017;169:381\u2013405. https:\/\/doi.org\/10.1016\/j.cell.2017.04.001.","journal-title":"Cell"},{"key":"877_CR42","doi-asserted-by":"publisher","first-page":"e109705.","DOI":"10.1371\/journal.pone.0109705","volume":"9","author":"M Rehan","year":"2014","unstructured":"Rehan M, Beg MA, Parveen S, Damanhouri GA, Zaher GF. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206. PLoS One. 2014;9:e109705. https:\/\/doi.org\/10.1371\/journal.pone.0109705.","journal-title":"PLoS One"},{"key":"877_CR43","doi-asserted-by":"publisher","first-page":"27653","DOI":"10.1074\/jbc.M802623200","volume":"283","author":"CJ Green","year":"2008","unstructured":"Green CJ, G\u00f6ransson O, Kular GS, Leslie NR, Gray A, Alessi DR, et al. Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B\/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J Biol Chem. 2008;283:27653\u201367. https:\/\/doi.org\/10.1074\/jbc.M802623200.","journal-title":"J Biol Chem."},{"key":"877_CR44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1089\/scd.2012.0220","volume":"22","author":"MP Kashyap","year":"2013","unstructured":"Kashyap MP, Singh AK, Kumar V, Yadav DK, Khan F, Jahan S, et al. Pkb\/Akt1 mediates Wnt\/GSK3\u03b2\/\u03b2-catenin signaling-induced apoptosis in human cord blood stem cells exposed to organophosphate pesticide monocrotophos. Stem Cells Dev. 2013;22:224\u201338. https:\/\/doi.org\/10.1089\/scd.2012.0220.","journal-title":"Stem Cells Dev"},{"key":"877_CR45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1159\/000369667","volume":"34","author":"X Gong","year":"2014","unstructured":"Gong X, Fan G, Wang W, Wang G. Trimetazidine protects umbilical cord mesenchymal stem cells against hypoxia and serum deprivation induced apoptosis by activation of Akt. Cell Physiol Biochem. 2014;34:2245\u201355. https:\/\/doi.org\/10.1159\/000369667.","journal-title":"Cell Physiol Biochem"},{"key":"877_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/jcp.24583","volume":"229","author":"Y-H Hsu","year":"2014","unstructured":"Hsu Y-H, Chang C-C, Yang N-J, Lee Y-H, Juan S-H. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014;229:1455\u201365. https:\/\/doi.org\/10.1002\/jcp.24583.","journal-title":"J Cell Physiol"},{"key":"877_CR47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.tcb.2017.08.002","volume":"27","author":"J Li","year":"2017","unstructured":"Li J, Labbadia J, Morimoto RI. Rethinking HSF1 in stress, development, and organismal health. Trends Cell Biol. 2017;27:895\u2013905. https:\/\/doi.org\/10.1016\/j.tcb.2017.08.002.","journal-title":"Trends Cell Biol"},{"key":"877_CR48","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1021\/pr201151a","volume":"11","author":"Y-M Xu","year":"2012","unstructured":"Xu Y-M, Huang D-Y, Chiu J-F, Lau ATY. Post-translational modification of human heat shock factors and their functions: a recent update by proteomic approach. J Proteome Res. 2012;11:2625\u201334. https:\/\/doi.org\/10.1021\/pr201151a.","journal-title":"J Proteome Res."},{"key":"877_CR49","doi-asserted-by":"publisher","first-page":"49460","DOI":"10.1074\/jbc.M406059200","volume":"279","author":"X Wang","year":"2004","unstructured":"Wang X, Grammatikakis N, Siganou A, Stevenson MA, Calderwood SK. Interactions between extracellular signal-regulated protein kinase 1, 14-3-3epsilon, and heat shock factor 1 during stress. J Biol Chem. 2004;279:49460\u20139. https:\/\/doi.org\/10.1074\/jbc.M406059200.","journal-title":"J Biol Chem."},{"key":"877_CR50","doi-asserted-by":"publisher","first-page":"29147","DOI":"10.1074\/jbc.M002169200","volume":"275","author":"IJ Xavier","year":"2000","unstructured":"Xavier IJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR, Ovsenek N. Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem. 2000;275:29147\u201352. https:\/\/doi.org\/10.1074\/jbc.M002169200.","journal-title":"J Biol Chem."},{"key":"877_CR51","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1126\/science.1165946","volume":"323","author":"SD Westerheide","year":"2009","unstructured":"Westerheide SD, Anckar J, Stevens SMJ, Sistonen L, Morimoto RI. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science. 2009;323:1063\u20136. https:\/\/doi.org\/10.1126\/science.1165946.","journal-title":"Science"},{"key":"877_CR52","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s00018-018-2836-6","volume":"75","author":"J Barna","year":"2018","unstructured":"Barna J, Csermely P, Vellai T. Roles of heat shock factor 1 beyond the heat shock response. Cell Mol Life Sci. 2018;75:2897\u2013916. https:\/\/doi.org\/10.1007\/s00018-018-2836-6.","journal-title":"Cell Mol Life Sci"},{"key":"877_CR53","doi-asserted-by":"publisher","first-page":"8982","DOI":"10.18632\/aging.102361","volume":"11","author":"D Liu","year":"2019","unstructured":"Liu D, Wu L, Wu Y, Wei X, Wang W, Zhang S, et al. Heat shock factor 1-mediated transcription activation of Omi\/HtrA2 induces myocardial mitochondrial apoptosis in the aging heart. Aging. 2019;11:8982\u201397. https:\/\/doi.org\/10.18632\/aging.102361.","journal-title":"Aging"},{"key":"877_CR54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.yjmcc.2020.10.010","volume":"150","author":"N Wang","year":"2020","unstructured":"Wang N, Ma H, Li J, Meng C, Zou J, Wang H, et al. HSF1 functions as a key defender against palmitic acid-induced ferroptosis in cardiomyocytes. J Mol Cell Cardiol. 2020;150:65\u201376. https:\/\/doi.org\/10.1016\/j.yjmcc.2020.10.010.","journal-title":"J Mol Cell Cardiol."},{"key":"877_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.yjmcc.2018.03.017","volume":"118","author":"S Wang","year":"2018","unstructured":"Wang S, Wu J, You J, Shi H, Xue X, Huang J, et al. HSF1 deficiency accelerates the transition from pressure overload-induced cardiac hypertrophy to heart failure through endothelial miR-195a-3p-mediated impairment of cardiac angiogenesis. J Mol Cell Cardiol. 2018;118:193\u2013207. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.03.017.","journal-title":"J Mol Cell Cardiol."},{"key":"877_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jb\/mvu031","volume":"156","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 2014;156:1\u201310. https:\/\/doi.org\/10.1093\/jb\/mvu031.","journal-title":"J Biochem"},{"key":"877_CR57","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.HYP.0000215207.54689.31","volume":"47","author":"Y Izumiya","year":"2006","unstructured":"Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47:887\u201393. https:\/\/doi.org\/10.1161\/01.HYP.0000215207.54689.31.","journal-title":"Hypertension"},{"key":"877_CR58","doi-asserted-by":"publisher","first-page":"I290","DOI":"10.1161\/CIRCULATIONAHA.105.001289","volume":"114","author":"I Friehs","year":"2006","unstructured":"Friehs I, Barillas R, Vasilyev NV, Roy N, McGowan FX, del Nido PJ. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation. 2006;114:I290\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.001289.","journal-title":"Circulation"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00877-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T02:04:22Z","timestamp":1664589862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-00877-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}